Association between atherogenic index of plasma and post-stroke depression: a cross-sectional study Authors: Demin Kong, Wei Zou Published: 2024 ABSTRACT ABSTRACTBackground: Few studies have established a link between the atherogenic index of plasma (AIP) and post-stroke depression (PSD). This study aims to further investigate the potential relationship between the AIP and PSD, and to provide references for the prevention and prognosis management of patients with PSD.Methods: A cross-sectional study was conducted using data from participants in the National Health and Nutrition Examination Survey from 2005 to 2018. Inclusion criteria required complete data on the AIP, stroke history, and depression status. Weighted logistic regression models and restricted cubic splines (RCS) were employed to examine the association between the AIP and PSD. By subgroup and interaction analyses, the stability associated with AIP and PSD was assessed between different subgroups.Results: Among the 32,364 participants ultimately enrolled in the study, 482 were diagnosed with PSD. In the weighted multivariate logistic regression adjustment model 3, AIP, as a continuous variable, was positively associated with the risk of PSD [odds ratio (OR) = 1.85, 95% confidence interval (CI): 1.18, 2.91; P = 0.007]. After the quartile classification of AIP, the adjusted model 3 showed that the risk of PSD in group Q4 was significantly higher than that in group Q1 (OR = 1.61, 95%CI:1.10, 2.34; P = 0.006). In the RCS linearity test, AIP was positively associated with the risk of PSD (Pnon-linear = 0.357). The interaction test demonstrated that AIP only had an interaction with gender (Pinteraction = 0.031) and not with other variables (Pinteraction > 0.05).Conclusion: AIP was positively associated with the prevalence of PSD, suggesting that AIP may be a promising predictor of the risk of developing PSD. In addition, the interaction of AIP and gender differences combined to influence the incidence of PSD.KEYWORDS: National health and nutrition examination survey, atherogenic index of plasma, stroke, depression, post-stroke depression, cross-sectional study Introduction Stroke, an acute cerebrovascular disease, can be induced by ischemic or hemorrhagic stroke due to brain tissue damage caused by sudden obstruction of blood flow to the brain or rupture of cerebral blood vessels (GBD 2019 Diseases and Injuries Collaborators, 2020). According to the most recent projections from the American Heart Association, by 2030, approximately 3.4 million adults in the U.S. aged ≥18 years will have experienced a stroke, representing 3.9% of the adult population and a 20.5% increase in prevalence since 2012 (Martin et al., 2024). The clinical symptoms of this disease are limb weakness, somatosensory abnormalities, dysphagia, slurred speech, cognitive impairment, and others, among which the movement disorders have serious impacts on the patients’ ability to perform activities of daily living as well as on their mental health and quality of life, which has made stroke a health issue that has sparked global concern (Ball et al., 2022; Mendelson & Prabhakaran, 2021). Depression is the most prevalent and severe neuropsychiatric complication following a stroke, with nearly one-third of stroke survivors experiencing post-stroke depression at any point during the five years post-stroke, which is associated with increased mortality rates in the 2–5 years following the event (Bartoli et al., 2013; Hackett & Pickles, 2014; Jørgensen et al., 2016). Research indicates that PSD follows a two-phase pattern, with depressive symptoms gradually intensifying over the first six months, slightly alleviating around the 12-month mark, and then worsening again in the second year post-stroke (Werheid, 2015). In contrast to patients with depression, patients with PSD almost always have symptoms of neurologic deficits resulting in weakened living ability, which suggests that PSD may be the result of a combination of post-stroke cognitive impairment, physical disabilities, social isolation, and psychological stress responses (Wu et al., 2020). Consequently, the early identification and treatment of PSD are crucial for improving patient prognosis. Nonetheless, the underlying mechanisms of PSD remain largely unexplored. Atherosclerosis, a disease in which lipid plaques accumulate in the walls of medium and large arteries leading to reduced or blocked blood flow, underlies the pathogenesis of many cardiovascular diseases (Libby, 2021). Dyslipidemia, an abnormality of lipoprotein metabolism in the body, mainly including total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) increase and/or high-density lipoprotein cholesterol (HDL-C) decrease, is the most important risk factor for atherosclerosis, and the main causative factor for cerebrovascular diseases that include stroke (Banerjee & Chimowitz, 2017). Various lipid markers have been utilised to evaluate the risk of stroke outcomes, including TC, HDL-C, TG, LDL-C and non-high-density lipoprotein cholesterol (Goldstein et al., 2023; Huang et al., 2020; Wang et al., 2020; Xiao et al., 2024; Zhang et al., 2012). However, the predictive value of these markers remains limited. Previous studies have demonstrated that AIP accurately responds to the association between protective and atherogenic lipoproteins, as well as better explaining the interactions between different lipid fractions, and was a sensitive indicator for assessing lipid disorders (Cai et al., 2019; Dobiásová, 2004). It is noteworthy that the AIP was first introduced by Dobiásová as a novel lipid index for assessing the body's susceptibility to atherosclerosis (Dobiásová, 2004). Elevated AIP may imply that adipocytes store excess TG as fat, which would increase the accumulation of cholesterol crystals in the inner layer of atherosclerotic arteries, leading to lumen narrowing and obstruction, and ultimately to atherosclerosis, and as a result, it may lead to a significant increase in the risk of ischemic stroke, and it may also affect prognostic outcomes in ischemic stroke (Liu et al., 2021). Depression may increase the risk of cardiovascular disease by causing impairment of endothelial function or exacerbating inflammatory responses to promote atherosclerosis progression (Krittanawong et al., 2023). In this view, many studies have also confirmed the significant negative impact of depression on the occurrence and outcome of cardiovascular disease (Harshfield et al., 2020; Li et al., 2022). The American Heart Association and the European Society of Cardiology suggest that treatment of depression may be key to improving the prognosis of coronary heart disease (Lichtman et al., 2014; Vaccarino et al., 2020). Studies have shown an association between AIP and the incidence of depression, meaning that higher levels of AIP can increase the risk of developing depression (Ye et al., 2024). AIP may also be used as a potential biomarker for the early diagnosis of cardiovascular disease events and a predictor of the severity of coronary artery disease (Fernández-Macías et al., 2019; Li et al., 2023). Currently, there are no studies on the correlation between AIP and PSD. This study intends to explore the correlation between AIP and the risk of developing PSD using data from the NHANES database. In addition, we hypothesised that elevated levels of AIP may be associated with an increased risk of PSD. Methods Data source This study was a cross-sectional observational study using data from participants in the NHANES database from 2005 to 2018. The study was reviewed and approved by the National Public Health Research Ethics Board and written informed consent was provided by the participants’ legal guardians or next of kin. Inclusion criteria for this study: participants included in the NHANES database from 2005 to 2018; exclusion criteria: (1) missing AIP data; (2) missing history of stroke; and (3) missing history of depression. Data collection In this study, a comprehensive approach was employed to collect demographic information using questionnaires. Participants were asked about their age, gender, race, marital status, and educational background. Additionally, the questionnaires gathered data regarding smoking status, personal medical history, specifically mental health conditions such as depression, previous incidents of stroke, cardiovascular diseases, and diabetes, as well as a detailed medication history that included antihypertensive, hypoglycemic, and lipid-lowering medications. This thorough collection of demographic and health-related data aimed to provide a robust context for analysing health outcomes in relation to the assessed variables. Furthermore, physical assessment were conducted to obtain objective measurements, including participants’ height, weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP). To ensure accuracy in metabolic assessments, blood samples were taken from participants in the morning, following an eight-hour fasting period. The analysis of these blood samples focused on critical parameters such as TG, HDL-C, fasting blood glucose (FBG), and glycosylated hemoglobin (HbA1c). These measurements were essential for evaluating the participants’ metabolic health and the potential risk factors associated with cardiovascular diseases and diabetes. Measurement of AIP and related covariates The selection of covariates in this study were based on previous literature and statistically significant differences at baseline, and multiple possible covariates were evaluated, including age, gender, race, marital status, education, body mass index (BMI), smoking status, comorbidities and treatments. The BMI was determined by dividing the participant's weight in kilograms by the square of their height in metres squared. Hypertension was defined rigorously, identifying individuals with SBP of 140 mmHg or greater and/or DBP of 90 mmHg or greater, and the diagnosis can be further supported by the use of antihypertensive medications or a self-reported history of hypertension (Chobanian et al., 2003). Similarly, the definition of diabetes were based on established clinical markers: FBG level of 126 mg/dL or higher, HbA1c of 6.5% or greater, or the reported use of hypoglycemic agents (American Diabetes Association, 2003). Finally, the exposure variable of primary interest in this investigation was the AIP, which serves as a key indicator of lipid metabolism. The AIP was calculated as the logarithm base 10 of the ratio of TG to HDL-C, with both parameters measured in millimoles per litre (Onat et al., 2010). Assessment of post-stroke depression The Patient Health Questionnaire (PHQ-9), developed by Spitzer in 1999, a self-assessment scale for depression, responds to a patient's psychosomatic activity in depression over a two-week period, and the nine items in the PHQ-9 derive from the Diagnostic and Statistical Manual of Mental Disorders (version 4) in the United States (Spitzer et al., 1999). Some studies have shown that the PHQ-9 has high reliability and validity for use in domestic and international populations, and can be used in a simple and practical way to screen for different levels of depressive disorders and to help physicians make clinical decisions and adjust treatment regimens (Kroenke et al., 2001; Lamers et al., 2008). Recommended by the American Heart Association in 2009 as a screening tool for depression in patients with cardiovascular disease (Lichtman et al., 2008). In this study, the severity of depressive symptoms in post-stroke patients was assessed using the PHQ-9 scale, which consists of nine items on a scale ranging from 0 to 27 points. Respondents reply to the nine questions using a four-point scale: 0 (not at all), 1 (several days), 2 (more than half the days), and 3 (nearly every day). Individual items assessed cognitive and emotional symptoms (‘no interest in doing things,’ ‘depressed,’ ‘feel bad about myself,’ ‘have trouble concentrating,’ ‘think it would be better if I were dead’) and somatic symptoms (‘difficulty sleeping’, ‘feeling tired’, ‘change in appetite’, ‘slow movement/speaking’). Participants with total scores ≥5 were considered to have screened positive for depressive episodes according to the standard (PHQ) cut-off value (Kroenke et al., 2001). Finally, we dichotomised the scores on the PHQ-9 scale, with those scores ≥5 considered to have depressive symptoms and, in contrast, those scores <5 identified as having no depressive symptoms. PSD was defined by screening participants with stroke by questionnaire and also fulfilling the PHQ-9 score ≥5. Statistical analysis Statistical analyses were executed with the use of RStudio (version 4.2.2). P value of less than 0.05 was deemed as indicating statistical significance. Due to the complex, stratified, multistage sampling frame employed by NHANES, the data were weighted according to the standard analysis guidelines established by NHANES. In this study, the Kolmogorov–Smirnov test was used to distinguish whether continuous variables were normal distribution or not. The mean ± standard deviation was used to express normal distribution variables and the median (interquartile range) [M (P25, P75)] was used to express skewed variables. Participants were categorised into four groups based on AIP quartiles (bounded by 25%, 50%, and 75%): Q1 (<−0.22; n = 7953), Q2 (−0.22 to <0.01; n = 7931), Q3 (0.01 to <0.26; n = 8262), and Q4 (≥0.26; n = 8218), with Q1 serving as the reference group (Shi & Wen, 2023). Odds ratio (OR) and 95% confidence interval (95% CI) were calculated using weighted logistic regression to assess the association between AIP and the risk of developing PSD. Weighted logistic regression analyses were performed using AIP as a continuous and categorical variable, respectively. To account for the influence of confounding factors, three models were calibrated: Model 1 included no variable adjustments; Model 2 controlled for gender, age, and race; Model 3 included a broader array of adjustments encompassing gender, age, race, education level, marital status, BMI, and smoking status. In this study, the restricted cubic spline (RCS) test was used to determine whether there existed a nonlinear relationship between AIP and the risk of developing PSD. Weighted logistic regression models were used for interaction and subgroup analyses based on age, gender, race, education level, marital status, BMI, smoking habits, comorbidities (diabetes, hypertension, and cardiovascular disease), and medication history (hypoglycemic, antihypertensive, and lipid-lowering medications). Statistical performance estimation was not performed in advance because the sample size of this study relied exclusively on the NHANES database. Results Study population The study used data from 2005 to 2018, and of the preliminary data provided, 70,190 cases participated, including 25,870 cases with missing AIP data, 10,010 cases with missing depression data, and 1,946 cases with missing stroke data. Ultimately, 32,364 participants with complete data were enrolled in the study. The specific exclusion and inclusion process was shown in Figure 1. Inclusion and exclusion process of study participants. Baseline characteristics of participants Ultimately, 32,364 participants with complete data were enrolled in the study, with the average age was (47.58 ± 16.89) years, of which 51.18% were female, 2.36% more than male. The majority of participants were non-Hispanic white, accounting for 68.46%. In addition, 482 patients (1.10%) had PSD. Table 1 categorises the AIP quartiles into four groups (AIP < −0.22, −0.22 ≤ AIP <0.01, 0.01 ≤ AIP <0.26, and AIP ≥0.26), with an overall post-stroke depression incidence of 1.10%, and incidence rates in each group (Q1-Q4) of 0.9%, 0.8%, 1.1%, and 1.6%, respectively. The incidence of post-stroke depression increased significantly with increasing AIP. Table 1.AIP quartiles present baseline characteristics of the study population. TotalQ1 (AIP < −0.22)Q2 (−0.22 ≤ AIP < 0.01)Q3 (0.01 ≤ AIP < 0.26)Q4 (AIP ≥ 0.26)PNumber323647953793182628218 Age, years47.58 ± 16.8945.40 ± 17.3447.13 ± 17.4848.89 ± 16.9648.78 ± 15.46<.001Gender, n (%) <.001Male15901 (48.82)2948 (34.8)3564 (44.2)4190 (51.4)5199 (65.0) Female16463 (51.18)5005 (65.2)4367 (55.8)4072 (48.6)3019 (35.0) Race, n (%) <.001Mexican American5155 (8.46)765 (5.5)1164 (7.8)1469 (9.3)1757 (11.2) Non-Hispanic White14061 (68.46)3215 (66.7)3384 (68.5)3681 (68.9)3781 (69.7) Non-Hispanic Black6673 (10.47)2525 (16.3)1876 (11.8)1389 (8.3)883 (5.4) Other6475 (12.62)1448 (11.5)1507 (11.9)1723 (13.5)1797 (13.7) Marital status, n (%) <.001Married/live with partner19446 (64.00)4244 (60.0)4596 (61.4)5160 (66.0)5446 (61.4) Other12918 (36.00)3709 (40.0)3335 (38.6)3102 (34.0)2772 (38.6) Education level, n (%) <.001High School or above24559 (84.59)6489 (88.4)6100 (85.4)6123 (83.3)5847 (81.3) Below high school7805 (15.41)1464 (11.6)1831 (14.6)2139 (16.7)2371 (18.7) Smoking, n (%) <.001Yes6630 (20.09)1421 (16.9)1558 (19.2)1714 (20.8)1937 (23.4) No25734 (79.91)6532 (83.1)6373 (80.8)6548 (79.2)6281 (76.6) BMI, kg/m228.90 ± 7.2425.84 ± 6.2228.27 ± 7.0730.20 ± 7.4731.29 ± 6.94<.001SBP, mmHg114.87 ± 34.26112.52 ± 32.17114.03 ± 34.33115.15 ± 35.60117.78 ± 34.65<.001DBP, mmHg66.33 ± 21.0364.89 ± 19.6065.63 ± 20.7166.37 ± 21.8868.42 ± 21.70<.001TG, mmol/L1.74 ± 1.470.73 ± 0.211.16 ± 0.271.69 ± 0.383.38 ± 2.10<.001HDL-C, mmol/L1.39 ± 0.421.81 ± 0.431.46 ± 0.301.25 ± 0.251.02 ± 0.22<.001Comorbidities, n (%) Diabetes <.001Yes5740 (13.22)715 (6.0)1127 (9.6)1715 (15.6)2183 (21.8) No26624 (86.78)7238 (94.0)6804 (90.4)6547 (84.8)6035 (78.2) Hypertension <.001Yes14035 (38.58)2738 (28.0)3255 (35.5)3894 (42.6)4148 (48.2) No18329 (61.42)5215 (72.0)4676 (64.5)4368 (57.4)4070 (51.8) Cardiovascular disease <.001Yes9822 (26.04)1837 (18.0)2249 (23.4)2825 (29.6)2911 (33.3) No22542 (73.96)6116 (82.0)5682 (76.6)5437 (70.4)5307 (66.7) Treatment, n (%) Hypoglycemic agents <.001Yes3814 (8.70)476 (3.8)761 (6.4)1150 (10.6)1427 (14.0) No28550 (91.30)7477 (96.2)7170 (93.6)7112 (89.4)6791 (86.0) Antihypertensive drugs <.001Yes10192 (27.29)1949 (19.2)2312 (24.3)2900 (30.7)3031 (34.9) No22172 (72.71)6004 (80.8)5619 (75.7)5362 (69.3)5187 (65.1) Lipid-lowering drugs <.001Yes7906 (22.38)1261 (13.8)1738 (18.9)2303 (25.8)2604 (31.0) No24458 (77.62)6692 (86.2)6193 (81.1)5959 (74.2)5614 (69.0) Outcomes, n (%) Post stroke depression (%) <.001Yes482 (1.10)92 (0.9)92 (0.8)134 (1.1)164 (1.6) No31882 (98.90)7861 (99.1)7839 (99.2)8128 (98.9)8054 (98.4) Note: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; AIP: atherogenic index of plasma; PHQ-9: patient health questionnaire-9. Data are presented as number (%) or mean ± standard deviation. AIP quartiles present baseline characteristics of the study population. Note: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; AIP: atherogenic index of plasma; PHQ-9: patient health questionnaire-9. Data are presented as number (%) or mean ± standard deviation. Association of AIP with risk of developing PSD The results of the multifactor weighted logistic regression analysis of AIP and the risk of developing PSD were shown in Table 2. In Model 1, when AIP was analysed as the continuous variable, there was significant independent positive correlation between AIP and the risk of PSD (OR = 1.90, 95%CI 1.34 ∼2.69; P < .001); The risk of PSD increased with increasing AIP quartiles, with higher OR in the Q4 group than in the Q1 group (OR = 1.82, 95%CI 1.30 ∼2.55). In Model 2, after adjusting for sex, race, and age, the positive association between the continuous variable AIP and the risk of developing PSD remained (OR = 2.44, 95%CI 1.62∼3.69; P < .001); the risk of PSD increased as the quartiles of AIP increased, with higher OR in the Q4 group than in the Q1 group (OR = 2.11, 95%CI 1.48∼3.02). Model 3 was comprehensively adjusted for covariates by adding education level, marital status, BMI, and smoking status to Model 2, and the adjusted results showed that the positive correlation between the continuous variable AIP and the risk of developing PSD remained stable (OR = 1.85, 95%CI 1.18∼2.91; P = 0.007); as the quartiles of AIP increased, the risk of PSD increased, with the OR higher in the Q4 group than in the Q1 group (OR = 1.61, 95%CI 1.10∼2.34). The RCS relationship between AIP and the risk of developing PSD was shown in Figure 2. When all confounding covariates were considered, there was positive association between AIP and the risk of developing PSD (Pnon-linear = 0.357). Table 2.Weighted logistic regression analysis of the correlation between AIP and the risk of developing PSD. Model 1Model 2Model 3 OR (95% CI)OR (95% CI)OR (95% CI)AIP1.90 (1.34, 2.69)2.44 (1.62, 3.69)1.85 (1.18, 2.91)P-value<.001<.0010.007Categories Q11.0 (Ref)1.0 (Ref)1.0 (Ref)Q20.93 (0.65, 1.33)0.92 (0.64, 1.33)0.83 (0.57, 1.19)Q31.30 (0.95, 1.79)1.29 (0.94, 1.78)1.05 (0.75, 1.47)Q41.82 (1.30, 2.55)2.11 (1.48, 3.02)1.61 (1.10, 2.34)P-value<.001<.0010.006Note: AIP: atherogenic index of plasma; PSD: post-stroke depression; OR: odds ratio; CI: confidence interval. Q1 as reference group. Model 1 was adjusted for none. Model 2 was adjusted for age, gender, race. Model 3was adjusted for age, gender, race, education level, marital status, BMI, smoking. Weighted logistic regression analysis of the correlation between AIP and the risk of developing PSD. Note: AIP: atherogenic index of plasma; PSD: post-stroke depression; OR: odds ratio; CI: confidence interval. Q1 as reference group. Model 1 was adjusted for none. Model 2 was adjusted for age, gender, race. Model 3was adjusted for age, gender, race, education level, marital status, BMI, smoking. Association between AIP and risk of PSD in RCS analysis. A linear association between AIP and the PSD was found (P < .001). The solid line and dashed line represent the estimated values and their corresponding 95% confidence interval. Adjustment factors included age, gender, race, education level, marital status, smoking, BMI, SBP, DBP, TG, HDL-C, comorbidities, treatment. Subgroup and interaction analysis To determine whether the relationship between AIP and the risk of developing PSD was consistent across subgroups, we performed stratification and interaction analyses. The subgroups were set up to incorporate variables with P < .05 in the univariate analyses of Table 1 that could cause confounding, and age (with the cutoff at 60 years) and body mass index (with cutoffs at 25 and 30) were included in the subgroup analyses after being transformed into categorical variables, as shown in Figure 3. The interaction test found that, except for gender (Pinteraction = 0.031), there were no statistically significant interaction between the other subgroups and AIP. Subgroup and interaction analysis. Adjustment for categorical variables that may cause confounding such as age, gender, race, education level, marital status, BMI, smoking status, diabetes, hypertension, cardiovascular disease, hypoglycemic agents, antihypertensive drugs, and lipid-lowering drugs. Discussion In this nationally representative study of the U.S. population, the positive association between AIP and PSD was found for the first time. Participants with AIP ≥0.01 (Q3 and Q4) had the significantly increased risk of developing PSD compared to participants with AIP < −0.22 (Q1). In patients with PSD, it was observed that there was a remarkable interaction between AIP and gender, with females having higher risk of developing PSD than males (females [1.38 (1.24, 1.53)], males [1.14 (1.00, 1.31)]; Pinteraction = 0.031). This was the first time researchers used the NHANES database to study the association between AIP and PSD. The mechanisms by which elevated AIP contributes to the risk of developing PSD remain to be explored. Dyslipidemia may play the connective role in this. Cholesterol, a vital lipid component in biological membranes, is essential for preserving the fluidity of cell membranes and ensuring proper synaptic function (Fisher et al., 2012; Kuwano et al., 2018). 5-hydroxytryptamine (5-HT) serves as a significant regulatory neurotransmitter, influencing a wide range of behaviours in the brain; compromised synaptic functions involving 5-HT are often linked to various mental health disorders (Kalinichenko et al., 2024). Kaplan et al. (1991) advanced the cholesterol-5-HT hypothesis, proposing that diminished cholesterol levels resulting from inadequate diet or synthesis inhibition could lead to reduced central activity of 5-HT. This hypothesis sheds light on the relationship between cholesterol and behaviours linked to depression, suicidal ideation, and aggression. Additionally, lower serum cholesterol metabolism may have a direct impact on lipid levels in the brain and the fluidity of cell membranes, subsequently affecting serotonergic neurotransmission (Cartocci et al., 2017; El-Sayyad, 2015). The abnormal lipid metabolism may be the pathophysiologic pathway shared by depression and PSD. Evidence supporting the connection between abnormal lipid metabolism and PSD was provided by the observation that both reduced HDL-C levels and elevated LDL/HDL ratios could act as risk factors for PSD (Shen et al., 2019). Furthermore, dyslipidemia that enhance atherosclerotic risk have been linked to the pathophysiological mechanisms of mood disorders (such as depression and bipolar disorder). The coexistence of mood disorders and cardiovascular disease can be partly attributed to elevated AIP and atherosclerotic indices that contribute to increased atherosclerotic risk (Nunes et al., 2015). Thus, high AIP-induced atherosclerosis plays an intermediary role in mood disorders and cardiovascular events. Notably, female stroke patients were found to be 20% more likely to experience PSD than their male counterparts, and the overall risk of developing PSD remained consistently greater for women stroke patients over a 1.5-year follow-up period (Mayman et al., 2021). Poynter Brittany et al.'s study also concluded that females have higher incidence of PSD (Poynter et al., 2009). These findings were consistent with the study's findings that gender differences were associated with the incidence of PSD, especially among female stroke patients who were at higher risk. Despite these findings, little knowledge exists about the factors that contribute to these differences. Possible explanations include physiological factors such as sex hormones and differences in genetics, psychological factors such as gender-specific symptom profiles or social factors such as gender-specific stressor exposure (Volz et al., 2021). Lee EJ et al. showed that female stroke patients were more likely to experience ‘reactive’ depressive symptoms after the stroke event, and that the depressive symptoms were more severe (Lee et al., 2020). Although the increased susceptibility to depression in women remains unclear, sex hormones may have an important role in influencing mood. Women experience more depressive symptoms during important times of abnormal changes in sex hormone levels, such as menopause (Morssinkhof et al., 2020). Lipocalin and leptin levels in postmenopausal women were significantly correlated with their depressive and anxiety symptoms, and higher lipocalin and lower leptin levels may serve as potential markers of depressive symptoms in postmenopausal women (Wu et al., 2021). This suggests that postmenopausal lipid metabolism disorders may be closely related to the high prevalence of depressive symptoms, and that regulation of lipid metabolism may be one of the ways to prevent and treat depressive symptoms in postmenopausal women. All of the above studies have demonstrated the effect of gender differences and the interaction between AIP on the incidence of PSD. Currently, the clinical approach to treating PSD indicates that combining psychotherapy, medication, and rehabilitation training can lead to optimal results (Wang et al., 2024). In managing patients affected by PSD, maintaining long-term follow-up and consistently monitoring AIP levels may facilitate the early identification of potential recurrence risks or the onset of new depressive symptoms, allowing for timely modifications to treatment plans. Moreover, proactive screening and addressing depression are essential to enhance both the physical and mental wellbeing of stroke survivors. The discovery of the link between AIP and PSD serves as a significant clinical guideline for PSD screening, as well as for researching its causes, devising treatment strategies, and assessing prognosis. Incorporating AIP into evaluations and therapeutic interventions is anticipated to enhance overall clinical results for patients. Nonetheless, the analyses in this study still have some limitations. Since the study design was cross-sectional, it was difficult to determine the causal relationship between the exposure factor (AIP) and the outcome variable (PSD), and thus more prospective studies are needed to elucidate this in the future. Due to the constraints of the NHANES database, only the PHQ-9 was utilised to measure both the presence and severity of depression, which differs from the evaluation of clinical depression. In addition, depression was measured with a self-report measure impacted by specific biases rather than a clinician-administered interview. It may also be worth noting context effects as a limitation of the current study. The study could not gather data regarding patients’ mental status prior to the stroke or their usage of antidepressant medications, nor could it acquire information about antiplatelet medication use after the stroke. These factors may influence the subsequent progression of stroke patients’ conditions and could have impacted the analytical results. Conclusions In summary, AIP, as a sensitive indicator for assessing dyslipidemia, suggests that dyslipidemia may increase the risk of developing PSD and considers the impact of gender differences on the development of PSD. Meanwhile, this study helps clinicians to consider assessing the lipid conditions of stroke patients, propose timely and targeted medication regimens and develop programmes for patients’ families to standardise their life care, and reduce the incidence of PSD, a high-mortality adverse sequela, by controlling lipid levels. Further studies will be needed in the future to clarify the exact mechanism of role of AIP in the pathogenesis of PSD as well as the effect of interaction between AIP and gender differences on the pathogenesis of PSD, and to develop preventive strategies and individualised treatments for patients and provide a basis for long-term comprehensive management of patients with PSD. Ethical approval and consent to participate All procedures performed in studies involving human participants were following the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Consent for publication Informed consent was obtained from all individual participants included in the study. Funding Statement The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Disclosure statement No potential conflict of interest was reported by the author(s). Data availability statement Publicly available datasets were analysed in this study. This data can be found here: https://www.cdc.gov/nchs/nhanes/index.htm. References Associated Data Data Availability Statement Publicly available datasets were analysed in this study. This data can be found here: https://www.cdc.gov/nchs/nhanes/index.htm.